Integration of pharmacokinetic and pharmacodynamic data to understand how a drug is likely to be distributed through the body over time and the access it will have to its molecular target. This understanding provides the basis for dosing strategies (see Dose finding and Dose fractionation study).
Typically, PK/PD modelling is used to simulate how a drug is distributed across different tissues (or ‘compartments’) over time. These models can be used to estimate drug concentrations at different body sites for different dosing regimens and drug effect.
Video definition by Ursula Theuretzbacher, Center for Anti-infective Agents (Austria).
PK/PD models in antibacterial development (Current Opinion in Microbiology, 2014)
REVIVE webinar: ‘PK-PD in support of accelerated programmes for antimicrobial development: how much is enough?’ by William Hope (GARDP, 2018)
REVIVE webinar: ‘Models for antimicrobial R&D: Computational modelling for population PK and PKPD’ by Lena Friberg & Elisabet Nielsen (GARDP, 2019)
REVIVE webinar: ‘PK/PD murine infection models: Focus on study elements, variability, and interpretation of results’ by Alexander J. Lepak (GARDP, 2020)
REVIVE webinar: ‘Probability of target attainment analyses for dose selection in antimicrobial drug development’ by Shampa Das (GARDP, 2020)
REVIVE webinar: ‘Test tube to patient: PK/PD of fixed dose beta-lactam/beta-lactamase inhibitor combinations’ by Vincent Tam (GARDP, 2020)